This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.

Oct 15, 2020 Issue
Trifarotene (Aklief) for the Treatment of Acne
Trifarotene is a monotherapy option for acne affecting the face and trunk and offers an alternative to topical antibiotics or anti-inflammatory agents for the management of moderate inflammatory and noninflammatory acne.

Sep 15, 2020 Issue
Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia
Lefamulin may be considered for patients hospitalized with community-acquired bacterial pneumonia.

Aug 15, 2020 Issue
Sarecycline (Seysara) for the Treatment of Acne
Sarecycline is a once-daily oral medication for patients with moderate to severe non-nodular acne. Its benefit over less expensive options has not been demonstrated.

Jul 15, 2020 Issue
Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure
Dapagliflozin can be added to existing treatment to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes who have established CVD or are at high risk of CVD. It may also decrease the risk of renal disease progression and death from renal failure.

Jun 15, 2020 Issue
Ozenoxacin (Xepi) for the Treatment of Impetigo
Ozenoxacin is an effective and safe topical quinolone treatment for bullous and nonbullous impetigo in patients as young as two months. However, it is expensive and some patients may have limited access because it is only available through a physician or hospital.

May 15, 2020 Issue
Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception
Annovera is an effective combined progestin/estrogen contraceptive device that can be used for one year.

Apr 15, 2020 Issue
Galcanezumab (Emgality) for Migraine and Cluster Headaches
In otherwise healthy adults with severe and frequent migraine or cluster headaches, galcanezumab may provide a modest reduction in debilitating headache frequency in the short term.

Mar 15, 2020 Issue
Esketamine (Spravato) for Treatment-Resistant Depression
Esketamine is an in-office treatment for patients with a severe major depressive disorder to be used in addition to oral antidepressant therapy.

Feb 15, 2020 Issue
Dupilumab (Dupixent) for Asthma
Dupilumab is an effective injectable drug that decreases asthma exacerbations and the need for an oral glucocorticoid in patients with moderate to severe asthma, particularly those with high eosinophil counts.

Jan 15, 2020 Issue
Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease
Revefenacin is a once-daily nebulized alternative to metered dose long-acting muscarinic antagonists for patients with moderate to severe COPD. Given its expense, complicated administration process, and lack of evidence that it improves key patient-oriented outcomes, its use should be limited to patients who are unable to use a metered dose inhaler.

Pages: 1 2 3 4 5 6 7 8 9 10 ... 15 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now